Trial Profile
Pazopanib vs. Pazopanib plus Gemcitabine in patients with relapsed or metastatic uterine leiomyosarcomas or uterine carcinosarcomas: a multi-center, randomized phase-II clinical trial of the NOGGO and AGO
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Gemcitabine
- Indications Carcinoma; Leiomyosarcoma; Sarcoma; Uterine cancer
- Focus Therapeutic Use
- Acronyms PazoDoble
- 29 Dec 2022 Status changed from recruiting to suspended.
- 29 Dec 2022 The trial has been suspended in Germany, according to European Clinical Trials Database record.
- 08 Jul 2019 Planned End Date changed from 1 Jun 2016 to 1 Dec 2023.